Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

1548 - A nomogram for predicting the Oncotype DX recurrence score in women with T1-3N0-1miM0 hormone receptor-positive, human epidermal growth factor-2 (HER2)-negative breast cancer


10 Oct 2016


Poster display




Annals of Oncology (2016) 27 (6): 43-67. 10.1093/annonc/mdw364


S. Lee

Author affiliations

  • Surgery, Asan Medical Center, University of Ulsan College of Medicine, 05505 - Seoul/KR


Abstract 1548


The aims of this preliminary study were to evaluate the association between the Oncotype DX (ODX) recurrence scores and traditional prognostic factors and to develop a nomogram that predict a subgroup of patients with low ODX recurrence scores (≤25), in whom addition of chemotherapy can be avoided.


Clinicopathological and immunohistochemical variables from a series of 396 T1-3N0-1miM0 hormone receptor-positive, human epidermal growth factor-2 (HER2)-negative breast cancer patients with available ODX test results at Asan Medical Center from 2010 to 2015 were retrospectively retrieved and analyzed. One hundred eight (27%) had positive axillary lymph node micrometastases, and 333 (84%) had ODX recurrence scores of ≤25. Logistic regression was performed to build a nomogram for predicting a low-risk subgroup of the ODX assay. The cutoff value of ODX recurrence scores for the low-risk subgroup was set at 25, which is used in the ongoing Oncotype DX phase 3 TAILORx trial.


Multivariate analysis revealed that estrogen receptor (ER) score, progesterone receptor (PR) score, lymphovascular invasion (LVI), nuclear grade, and Ki-67 had statistically significant association with the low-risk subgroup (all p values 


Low ODX recurrence score subgroup can be predicted by a nomogram incorporating five traditional prognostic factors: ER, PR, LVI, nuclear grade, and Ki-67. An independent prospective validation for the present nomogram is underway to confirm its accuracy.

Clinical trial identification

This is not the clinical trial.

Legal entity responsible for the study

Saebyul Lee


Asan Medical Center


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings